NU 2058

Cat. No. 3135

NU 2058 C12H17N5O [161058-83-9]

Price and Availability

For NU 2058 pricing & availability please select your country from the drop down menu:
Submit
By clicking submit you agree to accept a cookie from Tocris Bioscience. For details, please read our privacy and cookie policy.

Chemical Name: 6-(Cyclohexylmethoxy)-9H-purin-2-amine

Biological Activity

Cyclin-dependent kinase (cdk) 1 and cdk2 inhibitor (Ki values are 5 and 12 μM respectively). Inhibits growth of human tumor cells in vitro (mean GI50 = 13 μM). Also inhibits DNA topoisomerase II ATPase activity (IC50 = 300 μM).

Technical Data

M.Wt:
247.3
Formula:
C12H17N5O
Solubility:
Soluble to 100 mM in DMSO and to 10 mM in ethanol
Purity:
>99 %
Storage:
Store at +4°C
CAS No:
161058-83-9

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.

Certificate of Analysis / Product Datasheet / Safety Data Sheet

Jensen et al (2005) Substituted purine analogues define a novel structural class of catalytic topoisomerase II inhibitors. Cancer Res. 65 7470. PMID: 16103101.

Knockaert et al (2002) Pharmacological inhibitors of cyclin-dependent kinases. TiPS 23 417. PMID: 12237154.

Arris et al (2000) Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles. J.Med.Chem. 43 2797. PMID: 10956187.

If you know of a relevant reference for this product please let us know.

Citations are publications that use Tocris products. Selected citations for NU 2058 include:

Goonesekere et al (2014) A meta analysis of pancreatic microarray datasets yields new targets as cancer genes and biomarkers. PLoS One 9 e93046. PMID: 24740004.

Do you know of a great paper that uses NU 2058 from Tocris? If so please let us know.

View Related Products by Product Action

Keywords: NU 2058, supplier, Cdk1, cdk2, Topoisomerase, II, inhibits, inhibitors, Cyclin-Dependent, Protein, Kinases, DNA, Isomerases, NU2058, Tocris Bioscience, Cyclin-Dependent Protein Kinase Inhibitor products

Quick Order

Find multiple products by catalog number

divider line

Neurodegeneration Research Product Guide

Neurodegeneration Product Guide

Our Neurodegeneration guide highlights over 275 products for neurodegeneration research. Request copy or view PDF today.

divider line

Cancer Research Product Guide

Cancer Research Product Guide

Our Cancer Research Guide highlights over 750 products for cancer research. Request copy or view PDF today.

divider line

Kinase Inhibitor Toolbox

80 Kinase inhibitors
pre-dissolved in DMSO

Kinase Inhibitor Toolbox

Includes many of the latest kinase inhibitors to become commercially available. Covers a wide range of kinase targets including EGFR, MAPK and CDK.

divider line

Kinases Product Listing

Kinases Product Listing

Our Kinase listing highlights over 400 products for kinase research. Request copy or view PDF today.

divider line

New Products in this Area

RMM 46

MSK/RSK family kinase inhibitor

LTURM 34

Potent DNA-PK inhibitor

MLi-2

Potent and selective LRRK2 inhibitor

LTURM 36

PI 3-kinase δ inhibitor

PI 3065

Potent and selective PI 3-kinase p110δ inhibitor

AZ PFKFB3 67

Potent and selective PFKFB3 inhibitor

STOCK2S 26016

Lysine deficient protein kinase (WNK) signaling inhibitor

rac-CCT 250863

Potent Nek2 inhibitor

Roscovitine

Potent, selective cyclin-dependent kinase inhibitor

Enzastaurin

Potent PKCβ inhibitor

BMS 265246

Potent cdk1/2 inhibitor

Autocamtide-2-related inhibitory peptide, myristoylated

CaM kinase II inhibitor; enhanced cell permeable derivative of Autocamtide-2-related inhibitory peptide

MP A08

Selective ATP competitive SphK1 and 2 inhibitor; cell permeable

Akti-1/2

Potent and selective dual Akt1 and 2 inhibitor

Sign-up for new product e-alerts
divider line

LinkedIn Updates

Follow Tocris on LinkedIn

Follow us on LinkedIn!

Visit our LinkedIn page for the latest Tocris news, events and updates.